Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Non-Current Assets: 2022-2025

Historic Other Non-Current Assets for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $852,000.

  • Corvus Pharmaceuticals' Other Non-Current Assets rose 238.10% to $852,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $852,000, marking a year-over-year increase of 238.10%. This contributed to the annual value of $632,000 for FY2024, which is 610.11% up from last year.
  • According to the latest figures from Q3 2025, Corvus Pharmaceuticals' Other Non-Current Assets is $852,000, which was up 36.10% from $626,000 recorded in Q2 2025.
  • Corvus Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $852,000 during Q3 2025, with a 5-year trough of $89,000 in Q3 2023.
  • Moreover, its 3-year median value for Other Non-Current Assets was $129,000 (2024), whereas its average is $331,364.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first tumbled by 64.11% in 2023, then spiked by 610.11% in 2024.
  • Quarterly analysis of 4 years shows Corvus Pharmaceuticals' Other Non-Current Assets stood at $129,000 in 2022, then tumbled by 31.01% to $89,000 in 2023, then surged by 610.11% to $632,000 in 2024, then skyrocketed by 238.10% to $852,000 in 2025.
  • Its Other Non-Current Assets was $852,000 in Q3 2025, compared to $626,000 in Q2 2025 and $629,000 in Q1 2025.